Myeloma Australia welcomes today’s announcement by the Federal Government that the medicine Darzalex® (also known as daratumumab) will be available on the Pharmaceutical Benefits Scheme (PBS) for Aust...
Apr 2020 02
Lenalidomide (Revlimid®) maintenance post autologous stem cell transplant We are delighted to announce that as of 1 April 2020 the pharmaceutical benefits scheme (PBS) have listed lenalidomide (Revlim...
Mar 2020 13
Our Information and Support Groups are informal gatherings for people living with myeloma, their family and friends. These meetings provide a safe space to meet other members of the myeloma community ...
Dec 2019 20
Earlier this month, a team from Myeloma Australia visited Orlando, Florida in the USA for the annual American Society of Hematology (ASH) conference as invited guests of the International Myeloma Foun...
Sep 2019 19
A couple of weeks ago we sent out a special advocacy edition of the Muster to inform you of the latest submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) for the upcoming November PB...
Sep 2019 13
Cytogenetics is the study of chromosomes within a cell. Most commonly done at diagnosis, cytogenetic testing identifies the genetic mutations which characterise a person’s myeloma. This information he...
Feb 2018 23
A team from Myeloma Australia visited Atlanta USA in December 2017 as invited guests of the International Myeloma Foundation (IMF). This gave us the opportunity to attend the world’s biggest haematolo...
Dec 2017 22
The PBAC met in November this year to review the most recent applications for new drugs or amendments to the prescribing rules for existing drugs. Four myeloma drugs were reviewed during this meeting....